Sinovac Biotech (SVA) Downgraded by ValuEngine

Sinovac Biotech (SVA) Downgraded by ValuEngine


Separately, BidaskClub raised shares of Sinovac Biotech from a hold rating to a buy rating in a research note on Tuesday, March 20th. NASDAQ:SVA opened at $7.46 on Tuesday.



from Biotech News